Provided by Tiger Trade Technology Pte. Ltd.

Keros Therapeutics, Inc.

10.96
-0.0750-0.68%
Volume:103.36K
Turnover:1.13M
Market Cap:217.21M
PE:-3.53
High:11.12
Open:11.12
Low:10.72
Close:11.03
52wk High:22.55
52wk Low:9.69
Shares:19.83M
Float Shares:18.25M
Volume Ratio:0.56
T/O Rate:0.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1046
EPS(LYR):2.30
ROE:-17.16%
ROA:-11.78%
PB:0.83
PE(LYR):4.76

Loading ...

Keros Therapeutics Director Charles W. Newton Sells 551 Common Shares Worth $5,675.3

Reuters
·
Aug 21

Keros Therapeutics Director Jean Jacques Bieneaime Acquires USD 10,270 in Common Shares

Reuters
·
Aug 20

Keros Therapeutics Controller, VP Finance Annita Tanini Files Initial Beneficial Ownership Statement

Reuters
·
Aug 14

Keros Therapeutics (KROS) Receives a Hold from Bank of America Securities

TIPRANKS
·
Aug 11

Entrada Therapeutics Q2 Net Loss Narrows on Lower Costs

Reuters
·
Aug 05

Seres Therapeutics Q2 Net Income Turns Positive on VOWST Sale Gain

Reuters
·
Aug 05

Sweden's Xspray Posts Narrow Q2 Pretax Loss as Costs Fall

Reuters
·
Aug 05

Dianthus Therapeutics Q2 Net Loss Widens as R&D Costs Rise

Reuters
·
Aug 05

Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), ClearPoint Neuro (CLPT) and Keros Therapeutics (KROS)

TIPRANKS
·
Aug 04

Keros Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 04

Keros Therapeutics Inc : Leerink Partners Cuts Target Price to $23 from $30

THOMSON REUTERS
·
Aug 04

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Agios Pharma (AGIO), Novavax (NVAX) and Keros Therapeutics (KROS)

TIPRANKS
·
Aug 04

Keros updates TGF-β pipeline strategy in new presentation

TIPRANKS
·
Aug 04

Keros Q2 FY26 Net Loss Narrows to $28.7 Million; R&D Expenses Drop 48.74% to $22.3 Million

Reuters
·
Aug 04

Keros Therapeutics - Initiates Phase 2 Trial of Rinvatercept in Duchenne Muscular Dystrophy

THOMSON REUTERS
·
Aug 04

Keros Therapeutics Q2 Net Income USD -28.71 Million

THOMSON REUTERS
·
Aug 04

Keros Therapeutics - Cash and Cash Equivalents $257.60 Mln as of June 30, 2026

THOMSON REUTERS
·
Aug 04

Keros Therapeutics - Expects Cash to Fund Operations into First Half of 2028

THOMSON REUTERS
·
Aug 04

Keros Therapeutics to Receive $20 Million Takeda Milestone Payment for Elritercept Phase 3 Dosing

Reuters
·
Jul 31

Keros Therapeutics - Received $200 Mln Upfront from Takeda, Eligible for over $1.10 Bln in Milestones

THOMSON REUTERS
·
Jul 31